Supporting overseas biopharmaceutical companies' entry into the Japanese market through PATH-Solution

「As part of these efforts, the Company began providing PATH-Solution, a platform that comprehensively supports the entry of overseas emerging biopharmaceutical companies and others into the Japanese market, in January 2026. The service uses the functions of the Company's Total Supply Chain Service (TSCS) to provide end-to-end support from consideration of entry into the Japanese market through regulatory approval and post-launch distribution, with the aim of helping to resolve drug lags and losses by promoting the introduction of innovative pharmaceuticals from overseas.」